CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 113 filers reported holding CONCERT PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 1.73 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $4,397 | -99.9% | 753,140 | +19.7% | 0.02% | -4.3% |
| Q3 2022 | $4,214,000 | +18.7% | 629,299 | -25.4% | 0.02% | +27.8% |
| Q2 2022 | $3,551,000 | +32.7% | 843,325 | +6.2% | 0.02% | +63.6% |
| Q1 2022 | $2,675,000 | +8.5% | 794,106 | +1.4% | 0.01% | +22.2% |
| Q4 2021 | $2,465,000 | +7.8% | 782,813 | +11.8% | 0.01% | 0.0% |
| Q3 2021 | $2,287,000 | -11.6% | 700,340 | +14.3% | 0.01% | -10.0% |
| Q2 2021 | $2,586,000 | -2.9% | 612,711 | +14.8% | 0.01% | 0.0% |
| Q1 2021 | $2,662,000 | +104.0% | 533,573 | +416.6% | 0.01% | +100.0% |
| Q4 2020 | $1,305,000 | +18.4% | 103,276 | -7.9% | 0.01% | 0.0% |
| Q3 2020 | $1,102,000 | -30.5% | 112,185 | -29.6% | 0.01% | -28.6% |
| Q2 2020 | $1,585,000 | -3.2% | 159,328 | -13.9% | 0.01% | -22.2% |
| Q1 2020 | $1,637,000 | -23.3% | 185,060 | -19.9% | 0.01% | -10.0% |
| Q4 2019 | $2,133,000 | +36.3% | 231,168 | -13.1% | 0.01% | +42.9% |
| Q3 2019 | $1,565,000 | -61.7% | 265,869 | -22.0% | 0.01% | -65.0% |
| Q2 2019 | $4,088,000 | -36.7% | 340,702 | -36.3% | 0.02% | -28.6% |
| Q1 2019 | $6,459,000 | -21.6% | 535,173 | -18.5% | 0.03% | -31.7% |
| Q4 2018 | $8,242,000 | -40.3% | 656,504 | -29.4% | 0.04% | -28.1% |
| Q3 2018 | $13,797,000 | -12.9% | 929,772 | -1.2% | 0.06% | -16.2% |
| Q2 2018 | $15,841,000 | -18.2% | 941,282 | +11.3% | 0.07% | -19.0% |
| Q1 2018 | $19,355,000 | +150.9% | 845,419 | +183.7% | 0.08% | +154.5% |
| Q4 2017 | $7,713,000 | +1066.9% | 298,036 | +355.1% | 0.03% | +1000.0% |
| Q3 2016 | $661,000 | -78.6% | 65,484 | -76.2% | 0.00% | -81.2% |
| Q2 2016 | $3,091,000 | +120.9% | 275,138 | +168.7% | 0.02% | +128.6% |
| Q1 2016 | $1,399,000 | +71.0% | 102,403 | +137.6% | 0.01% | +75.0% |
| Q4 2015 | $818,000 | +193.2% | 43,107 | +188.9% | 0.00% | +100.0% |
| Q3 2015 | $279,000 | – | 14,922 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| L1 Capital Pty Ltd | 1,050,124 | $10,312,000 | 3.31% |
| Alambic Investment Management, L.P. | 19,934 | $196,000 | 2.15% |
| INGALLS & SNYDER LLC | 1,363,603 | $13,391,000 | 0.92% |
| ACUTA CAPITAL PARTNERS, LLC | 300,000 | $2,946,000 | 0.80% |
| RA Capital Management | 1,858,474 | $18,250,000 | 0.33% |
| Perceptive Advisors | 2,150,641 | $21,119,000 | 0.31% |
| SPHERA FUNDS MANAGEMENT LTD. | 310,000 | $3,044,000 | 0.30% |
| Eversept Partners, LP | 103,829 | $1,019,601 | 0.23% |
| Opaleye Management Inc. | 100,000 | $982,000 | 0.19% |
| GSA CAPITAL PARTNERS LLP | 58,095 | $570,000 | 0.10% |